Inhibikase shares jump 20% intraday after H.C. Wainwright initiates coverage with Buy rating and $8 price target.

Inhibikase Therapeutics (NASDAQ:IKT) surged 20% intraday following H.C. Wainwright’s initiation of coverage with a "Buy" rating and $8.00 price target, representing a 385% upside from its $1.65 share price. The firm highlighted the company’s advancement of IKT-001, a prodrug of imatinib, into a global Phase 3 trial for pulmonary arterial hypertension (PAH) in Q1 2026, citing its potential to address unmet medical needs with improved tolerability over existing therapies. The analyst consensus reinforces optimism, with a $5.60 average target from five firms and strong liquidity metrics. Additionally, Inhibikase’s $100 million public offering to fund late-stage development further underscored its strategic momentum, aligning with the stock’s sharp intraday rally.